CSR Program: Drugs for Neglected Disease Initiative | Takeda Pharmaceuticals

Five people sitting down and six people standing up in waiting room

Expanding neglected patient's access to quality diagnosis and treatment in disease-endemic countries

Equipping facilities with safe, effective tools, training primary health workers and supporting community awareness and behaviors

Drugs for Neglected Diseases initiative logo

The Program

Partner: DNDi(Drugs for Neglected Diseases initiative)

Budget: 1 billion yen

Term: 5 years

Launch: 2019

Area: 16 countries accross Africa, Asia and South America

Visit the DNDi websiteGo to https://dndi.org/

Over one billion people, including 500 million children, are affected by neglected tropical diseases (NTDs), a group of diseases that disproportionally prevail in tropical and subtropical countries. DNDi targets five NTDs: sleeping sickness, Chagas disease, leishmaniasis, onchocerciasis and mycetoma. These are characterized by significant morbidity and/or mortality and have been prioritized due to the current limited availability and accessibility of effective diagnostic and treatment.

Women reading provided dndi content

Physicians treating woman and child

Have more questions?

Contact us if you'd like more information about our Global CSR Program.